- 6168-72-51-Propanol, 2-amino-
- 61687-26-17-chloro-2-phenyl-Quinoline
- 6168-83-8Butanoic acid,3-hydroxy-, (3S)-
- 61689-35-81,2,4-Thiadiazole-3-carboxylicacid, 5-phenyl-, ethyl ester
- 61689-36-9ETHYL 5-(4-CHLOROPHENYL)-1,2,4-THIADIAZOLE-3-CARBOXYLATE
- 61689-98-31H-Benzimidazole-2-ethanethioamide
- 61690-08-21H-Benzimidazole,1-methyl-2-[(4-methyl-2-thiazolyl)methyl]-
- 6169-06-8D(+)-2-Octanol
- 616-91-1N-Acetyl-cysteine
- 61692-83-92-Butenoic acid,2-methyl-, propyl ester, (2E)-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Mefenamic acid |
EINECS | 200-513-1 |
| CAS No. | 61-68-7 | Density | 1.203 g/cm3 |
| PSA | 49.33000 | LogP | 3.81820 |
| Solubility | It is soluble in acetone, chloroform, dichloromethane, methanol. Insoluble in water. | Melting Point |
230 °C |
| Formula | C15H15NO2 | Boiling Point | 398.8 °C at 760 mmHg |
| Molecular Weight | 241.29 | Flash Point | 195 °C |
| Transport Information | N/A | Appearance | light yellow solid |
| Safety | 22-36 | Risk Codes | 22-40-20/21/22 |
| Molecular Structure |
|
Hazard Symbols |
 Xn
|
| Synonyms |
Acido mefenamico;Acido mefenamico [INN-Spanish];Acidum mefenamicum;Acidum mefenamicum [INN-Latin];Anthranilic acid, N-2,3-xylyl;Bafhameritin-M;Benzoic acid, 2-((2,3-dimethylphenyl)amino)-;Bonabol;Fenamin;HL 1;Lysalgo;Mefacit;Mefedolo;Rolan;Ponstan forte;Ponalar;Parkemed;Namphen;N-(2,3-Xylyl)-2-aminobenzoic acid;Mycasaal; |
Article Data | 53 |
Mefenamic acid Synthetic route
- 61-68-7
mefenamic Acid
| Conditions | Yield |
|---|---|
| With hydrogen In methanol at 50℃; under 3750.38 Torr; Flow reactor; chemoselective reaction; | 98% |
| Conditions | Yield |
|---|---|
| Stage #1: ortho-chlorobenzoic acid With sodium carbonate In N,N-dimethyl-formamide at 80℃; for 0.5h; Stage #2: 2,3-Dimethylaniline With manganese(II) acetate In water; N,N-dimethyl-formamide; toluene at 120 - 130℃; Reagent/catalyst; | 94.8% |
| Stage #1: ortho-chlorobenzoic acid With sodium carbonate In N,N-dimethyl-formamide at 80℃; for 1.16667h; Stage #2: 2,3-Dimethylaniline With copper In water; N,N-dimethyl-formamide; toluene at 104 - 123℃; | 91.3% |
| With copper; sodium carbonate In N,N-dimethyl-formamide at 140℃; for 2h; | 90% |
| Conditions | Yield |
|---|---|
| With sodium acetate; copper (I) acetate In water for 1.5h; Heating; | 93% |
| With copper; potassium carbonate In N,N-dimethyl-formamide at 100℃; for 12h; Schlenk technique; Inert atmosphere; |
- 13481-67-9
2-[(2,3-dimethylphenyl)amino]benzonitrile
- 61-68-7
mefenamic Acid
| Conditions | Yield |
|---|---|
| With methanol; potassium hydroxide In water at 100℃; for 12h; Schlenk technique; | 91% |
| With water; potassium hydroxide In methanol for 12h; Reflux; | |
| With water; potassium hydroxide In ethanol at 95℃; for 20h; Inert atmosphere; | 161 mg |
- 61-68-7
mefenamic Acid
| Conditions | Yield |
|---|---|
| With potassium hydroxide In ethanol at 110℃; for 18h; Sealed tube; | 90% |
| Conditions | Yield |
|---|---|
| With copper diacetate In isopropyl alcohol for 23h; Heating; | 54% |
| With copper diacetate In isopropyl alcohol at 85℃; for 23h; | 54% |
| copper diacetate In isopropyl alcohol at 80℃; for 15h; | 90 % Spectr. |
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: Pd-PEPPSI-IPrAn; caesium carbonate / 1,4-dioxane / 24 h / 80 °C / Inert atmosphere 2: water; potassium hydroxide / methanol / 12 h / Reflux View Scheme |
| Conditions | Yield |
|---|---|
| With hydrogenchloride; water pH=2; Kinetics; Solvent; Reagent/catalyst; |
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1: tetrahydrofuran; diethyl ether / 0 - 20 °C 2: cesium fluoride / tetrahydrofuran / 16 h / 70 °C / Inert atmosphere 3: potassium hydroxide; methanol / water / 12 h / 100 °C / Schlenk technique View Scheme |
- 55591-34-9
N-(2,3-dimethylphenyl)cyanamide
- 61-68-7
mefenamic Acid
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: cesium fluoride / tetrahydrofuran / 16 h / 70 °C / Inert atmosphere 2: potassium hydroxide; methanol / water / 12 h / 100 °C / Schlenk technique View Scheme |
Mefenamic acid Chemical Properties
Molecular structure of Mefenamic acid (CAS NO.61-68-7) is:
Product Name: Mefenamic acid
CAS Registry Number: 61-68-7
IUPAC Name: 2-(2,3-Dimethylanilino)benzoic acid
Molecular Weight: 241.2851 [g/mol]
Molecular Formula: C15H15NO2
XLogP3: 5.1
H-Bond Donor: 2
H-Bond Acceptor: 3
EINECS: 200-513-1
Melting Point: 230 °C
Surface Tension: 51.7 dyne/cm
Density: 1.203 g/cm3
Flash Point: 195 °C
Enthalpy of Vaporization: 68.49 kJ/mol
Boiling Point: 398.8 °C at 760 mmHg
Vapour Pressure: 4.45E-07 mmHg at 25°C
Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts; Amino Acids 13C, 2H, 15N; Amino Acids & Derivatives; Intermediates & Fine Chemicals; Pharmaceuticals; API's
Mefenamic acid Uses
Mefenamic acid (CAS NO.61-68-7) is a non-steroidal anti-inflammatory drug, so it can be used to treat pain, including menstrual pain, also ot is typically prescribed for oral administration. However, it decreases inflammation (swelling) and uterine contractions by a still unknown mechanism and it is thought to be related to the inhibition of prostaglandin synthesis.
Mefenamic acid Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LD50 | intravenous | 100mg/kg (100mg/kg) | Current Medical Research and Opinion. Vol. 4, Pg. 17, 1976. | |
| man | TDLo | oral | 14285ug/kg/3D (14.285mg/kg) | British Journal of Clinical Practice. Vol. 49, Pg. 161, 1995. | |
| man | TDLo | oral | 14285ug/kg/3D (14.285mg/kg) | British Journal of Clinical Practice. Vol. 49, Pg. 161, 1995. | |
| man | TDLo | oral | 257mg/kg/12D- (257mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | British Medical Journal. Vol. 291, Pg. 661, 1985. |
| man | TDLo | oral | 840mg/kg/6W-I (840mg/kg) | GASTROINTESTINAL: ULCERATION OR BLEEDING FROM LARGE INTESTINE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | British Medical Journal. Vol. 287, Pg. 1626, 1983. |
| mouse | LD50 | intramuscular | 400mg/kg (400mg/kg) | Pharmaceutical Chemistry Journal Vol. 17, Pg. 353, 1983. | |
| mouse | LD50 | intraperitoneal | 120mg/kg (120mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 36, 1969. | |
| mouse | LD50 | intravenous | 96mg/kg (96mg/kg) | Yakugaku Zasshi. Journal of Pharmacy. Vol. 89, Pg. 1392, 1969. | |
| mouse | LD50 | oral | 525mg/kg (525mg/kg) | Journal de Pharmacologie. Vol. 2, Pg. 259, 1971. | |
| mouse | LDLo | subcutaneous | > 2gm/kg (2000mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1579, 1970. |
| rat | LD50 | intraperitoneal | 327mg/kg (327mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
| rat | LD50 | intravenous | 112mg/kg (112mg/kg) | Current Medical Research and Opinion. Vol. 4, Pg. 17, 1976. | |
| rat | LD50 | oral | 740mg/kg (740mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 28, Pg. 99, 1981. |
| women | LDLo | oral | 280mg/kg/2W-I (280mg/kg) | LIVER: LIVER FUNCTION TESTS IMPAIRED KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" BLOOD: OTHER HEMOLYSIS WITH OR WITHOUT ANEMIA | Drug Safety. Vol. 6, Pg. 230, 1991. |
| women | TDLo | oral | 20mg/kg/4D-I (20mg/kg) | GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS | Canadian Medical Association Journal. Vol. 126, Pg. 894, 1982. |
| women | TDLo | oral | 450mg/kg (450mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: TOXIC PSYCHOSIS BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | South African Medical Journal. Vol. 67, Pg. 823, 1985. |
| women | TDLo | unreported | 120mg/kg/4D (120mg/kg) | BEHAVIORAL: WITHDRAWAL SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Lancet. Vol. 2, Pg. 745, 1980. |
Mefenamic acid Safety Profile
Safty information about Mefenamic acid (CAS NO.61-68-7) is:
Hazard Codes: 
Xn
Risk Statements: 22-40-20/21/22
R22:Harmful if swallowed.
R40:Limited evidence of a carcinogenic effect.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 22-36
S22:Do not breathe dust.
S36:Wear suitable protective clothing.
WGK Germany: 3
RTECS: CB4550000
Mefenamic acid Specification
Mefenamic acid , its cas register number is 61-68-7. It also can be called Mefenamic acid [USAN:INN:BAN:JAN] ; 2-((2,3-Dimethylphenyl)amino)benzoic acid ; 2-Diphenylaminecarboxylic acid, 2',3'-dimethyl- ; Ac. mefenamico ; Ac. mefenamico [Italian] ; Acide mefenamique ; Acide mefenamique [French] ; Acide mefenamique [INN-French] ; Acido mefenamico ; Acido mefenamico [INN-Spanish] ; Acidum mefenamicum ; Acidum mefenamicum [INN-Latin] ; Anthranilic acid, N-2,3-xylyl- ; Bafhameritin-M ; Benzoic acid, 2-((2,3-dimethylphenyl)amino)- ; Benzoic acid, 2-(2,3-dimethylphenyl)amino- ; Bonabol ; Fenamin ; HL 1 ; Lysalgo ; Mefacit ; Mefedolo ; Mefenamate ; Mefenamic acid ; Mefenaminsaeure ; Mephenamic acid ; Mephenaminic acid ; Methenamic acid ; Mycasaal ; N-(2,3-Dimethylphenyl)anthranilic acid ; N-(2,3-Xylyl)-2-aminobenzoic acid ; N-2,3-Xylylanthranilic acid ; Namphen ; Parkemed ; Ponalar ; Ponstan ; Ponstan forte ; Ponstel ; Rolan ; Tamany Bonsan ; Tanston ; Vialidon . It is a light yellow solid. Since it plays a significant role in mefenamic acid elimination, patients with known liver deficiency may be prescribed lower doses. Kidney deficiency may also cause accumulation of the drug and its metabolites in the excretory system. Therefore patients suffering from renal conditions should not be prescribed mefenamic acid.
What can I do for you?
Get Best Price
